Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0085580 (
essential hypertension
)
14,686
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
As a member of the ubiquitin-specific protease (USP) family,
USP22
could remove ubiquitin moieties from its target proteins to control the function of the target proteins. Accumulating studies show that
USP22
essentially participates in diverse types of cancer as an oncogene-like protein. However, the roles of
USP22
in human pancreatic ductal adenocarcinoma (PDAC) and the underlying mechanism are unknown. Here we report that
USP22
promotes the growth of PDAC cells by promoting the expression of dual-specificity tyrosine regulated kinase 1A (DYRK1A). Our results showed that the expression levels of
USP22
were up-regulated in human PDAC tissues and cell lines (BxPC-3, AsPC-1, MIA-PaCa-2, PANC-1, and CAPAN-1). Lentivirus-mediated knockdown of
USP22
repressed the rate of proliferation and capacity of colony formation of BxPC3 and CAPAN1 cancer cells and
USP22
overexpression promoted the proliferation and capacity of the colony formation of BxPC3 and CAPAN1 cancer cells. The further mechanism study showed that
USP22
elevated the expression of the mRNA and protein levels of DYRK1A in PDAC cancer cells. Inhibition of DYRK1A with
EHT
-5732 or lentivirus-mediated knockdown of DYRK1A blocked the function of
USP22
overexpression in the regulation of the proliferation and colony formation of PDAC cells. Taken together, our findings demonstrated that
USP22
overexpression in PDAC promoted the growth of the cancer cells partially through upregulating the expression of DYRK1A.
...
PMID:The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma. 3268 47